Objective
To summarize the clinical experiences with singleâport (SP) robotâassisted radical prostatectomy (RARP) reported in the literature and to describe the periâoperative and shortâterm outcomes of this procedure.
Material and Methods
A systematic review of the literature was performed in December 2019 using Medline (via PubMed), Embase (via Ovid), Cochrane databases, Scopus and Web of Science (PROSPERO registry number 164129). All studies that reported intraâ and periâoperative data on SPâRARP were included. Cadaveric series and perineal or partial prostatectomy series were excluded.
Results
The pooled mean operating time, estimated blood loss, length of hospital stay and catheterization time were 190.55Â min, 198.4Â mL, 1.86Â days and 8.21Â days, respectively. The pooled mean number of lymph nodes removed was 8.33, and the pooled rate of positive surgical margins was 33%. The pooled minor complication rate was 15%. Only one urinary leakage and one major complication (transient ischaemic attack) were recorded. Regarding functional outcomes, pooled continence and potency rates at 12Â weeks were 55% and 42%, respectively.
Conclusions
The present analysis confirms that SPâRARP is safe and feasible. This novel robotic platform resulted in similar intraâoperative and periâoperative outcomes to those obtained with the standard multiport da Vinci system. The advantages of single incision can be translated into a preservation of the patientâs body image and selfâesteem and cosmesis, which have a great impact on a patient's quality of life.